WO2002043647A3 - Oncolytic virus - Google Patents

Oncolytic virus Download PDF

Info

Publication number
WO2002043647A3
WO2002043647A3 PCT/CA2001/001703 CA0101703W WO0243647A3 WO 2002043647 A3 WO2002043647 A3 WO 2002043647A3 CA 0101703 W CA0101703 W CA 0101703W WO 0243647 A3 WO0243647 A3 WO 0243647A3
Authority
WO
WIPO (PCT)
Prior art keywords
oncolytic virus
disclosed
reassortants
viruses
pkr
Prior art date
Application number
PCT/CA2001/001703
Other languages
French (fr)
Other versions
WO2002043647A2 (en
Inventor
Earl Garnet Brown
Jean Lutamyo Mbisa
John Cameron Bell
David Francis Stodjl
Original Assignee
Univ Ottawa
Earl Garnet Brown
Jean Lutamyo Mbisa
John Cameron Bell
David Francis Stodjl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ottawa, Earl Garnet Brown, Jean Lutamyo Mbisa, John Cameron Bell, David Francis Stodjl filed Critical Univ Ottawa
Priority to AU2002220416A priority Critical patent/AU2002220416A1/en
Priority to JP2002545626A priority patent/JP2004519431A/en
Priority to EP01998300A priority patent/EP1339736A2/en
Priority to CA002430495A priority patent/CA2430495A1/en
Priority to US10/433,064 priority patent/US20040115170A1/en
Publication of WO2002043647A2 publication Critical patent/WO2002043647A2/en
Publication of WO2002043647A3 publication Critical patent/WO2002043647A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Abstract

Methods of reducing the viability of a tumor cell, infecting a neoplasm in a mammal, utilizing certain non-naturally occuring viruses are disclosed. Viral reassortants, for example reovirus reassortants, and techniques for identifying PKR-sensitive viruses are also disclosed.
PCT/CA2001/001703 2000-12-01 2001-11-30 Oncolytic virus WO2002043647A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002220416A AU2002220416A1 (en) 2000-12-01 2001-11-30 Oncolytic virus
JP2002545626A JP2004519431A (en) 2000-12-01 2001-11-30 Oncolytic virus
EP01998300A EP1339736A2 (en) 2000-12-01 2001-11-30 Oncolytic virus
CA002430495A CA2430495A1 (en) 2000-12-01 2001-11-30 Oncolytic virus
US10/433,064 US20040115170A1 (en) 2001-11-30 2001-11-30 Oncolytic virus

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25013100P 2000-12-01 2000-12-01
US60/250,131 2000-12-01
US32701601P 2001-10-05 2001-10-05
US60/327,016 2001-10-05

Publications (2)

Publication Number Publication Date
WO2002043647A2 WO2002043647A2 (en) 2002-06-06
WO2002043647A3 true WO2002043647A3 (en) 2003-01-03

Family

ID=26940619

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CA2001/001703 WO2002043647A2 (en) 2000-12-01 2001-11-30 Oncolytic virus
PCT/US2001/045108 WO2002050304A2 (en) 2000-12-01 2001-12-03 Oncolytic virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045108 WO2002050304A2 (en) 2000-12-01 2001-12-03 Oncolytic virus

Country Status (5)

Country Link
EP (1) EP1339736A2 (en)
JP (1) JP2004519431A (en)
AU (2) AU2002220416A1 (en)
CA (1) CA2430495A1 (en)
WO (2) WO2002043647A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
EP1917351A4 (en) 2005-08-01 2009-12-16 Univ Technologies Int Attenuated reovirus
CA2678721C (en) 2007-03-12 2018-02-13 Oncolytics Biotech Inc. Reoviruses having modified sequences
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2019237063A1 (en) * 2018-06-07 2019-12-12 Emory University Modified reoviruses, particles, and uses in treating proliferative disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008692A1 (en) * 1997-08-13 1999-02-25 Oncolytics Biotech, Inc. Reovirus for the treatment of neoplasia
WO1999045783A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
WO2000050051A2 (en) * 1999-02-24 2000-08-31 Oncolytics Biotech, Inc. Reovirus for the treatment of cellular proliferative disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008692A1 (en) * 1997-08-13 1999-02-25 Oncolytics Biotech, Inc. Reovirus for the treatment of neoplasia
WO1999045783A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy
WO2000050051A2 (en) * 1999-02-24 2000-08-31 Oncolytics Biotech, Inc. Reovirus for the treatment of cellular proliferative disorders

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BROWN E.G. ET AL: "Bioengineering the oncolytic potential or reovirus", GENE THERAPY, vol. 8, no. Suppl. 1, October 2001 (2001-10-01), pages S7, XP008006830 *
COFFEY M.C. ET AL.: "Reovirus therapy of tumors with activated Ras pathway.", SCIENCE, vol. 282, 13 November 1998 (1998-11-13), pages 1332 - 1334, XP002210019 *
HALLER B.L.: "Genetic mapping of reovirus virulence and organ tropism in severe combined immunodeficient mice: organ-specific virulence genes.", J. VIROL., vol. 69, no. 1, January 1995 (1995-01-01), pages 357 - 364, XP002210022 *
MBISA J.L. ET AL.: "Reovirus mu2 protein determines strain-specific differences in the rate of viral inclusion formation in L929 cells", VIROLOGY, vol. 272, 20 June 2000 (2000-06-20), pages 16 - 26, XP002210023 *
NORMAN K.L. & LEE P.W.K.: "Reovirus as a novel oncolytic agent", J. CLIN. INVEST., vol. 105, no. 8, April 2000 (2000-04-01), pages 1035 - 1038, XP002210021 *
TYLER K.L. ET AL.: "Differences in the capacity of reovirus to induce apoptosis are determined by the viral attachment protein sigma1", J. VIROL., vol. 69, no. 11, November 1995 (1995-11-01), pages 6972 - 6979, XP002210020 *

Also Published As

Publication number Publication date
CA2430495A1 (en) 2002-06-06
WO2002050304A2 (en) 2002-06-27
JP2004519431A (en) 2004-07-02
AU2002220416A1 (en) 2002-06-11
WO2002043647A2 (en) 2002-06-06
EP1339736A2 (en) 2003-09-03
WO2002050304A3 (en) 2002-11-28
AU2002243257A1 (en) 2002-07-01

Similar Documents

Publication Publication Date Title
GB2386895B (en) An herpes simplex virus complex
PT1685243E (en) Immortalized avian cell lines for virus production
WO2003078592A3 (en) Method for the purification, production and formulation of oncolytic adenoviruses
ATE466932T1 (en) REPRODUCTION OF VIRUSES IN CELL CULTURE
WO2001053506A3 (en) Virus strains for the oncolytic treatment of cancer
PT891420E (en) PROCESSES FOR THE REPLICATION OF INFLUENZA VIRUSES IN A CELLULAR CULTURE AND THE INFLUENZA VIRUS THAT CAN BE OBTAINED THROUGH THE PROCESS
NO20004104L (en) Preparations comprising viruses and methods for concentrating virus preparations
WO2005087931A8 (en) Modified oncolytic viruses
HK1019233A1 (en) Animal cells and processes for the replication of influenza viruses
WO2002043647A3 (en) Oncolytic virus
IS2811B (en) Use of HPV16 and HPV18 virus-like particles against one or more of the tumor-causing HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
WO2005032487A3 (en) Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus
PT1434858E (en) Method for the amplification of a poxvirus under serum free conditions
ATE260957T1 (en) PIGMENT PREPARATIONS CONTAINING ALKOXYLATED POLYETHYLENEIMINE
WO2007053165A3 (en) Virus protein microarray and uses therefor
EP0806203A3 (en) Anti-viral compositions
DE60234496D1 (en) VIRUS VECTOR FOR GENE THERAPY
ATE278795T1 (en) HERPES VIRUSES FOR MODULATING AN IMMUNE RESPONSE
WO2006052826A3 (en) Methods for preparing cells and viruses
AU1386100A (en) Stable, attenuated rabies virus mutants and live vaccines thereof
WO2005002607A3 (en) Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
DE122011100041I1 (en) In vitro reconstitution of segmented, negative-strand RNA viruses.
ZA200205470B (en) Virus strains for the oncolytic treatment of cancer.
AU2002221515A1 (en) A virus which can express tumor angiostatin factor with high efficiency in specific tumor cells and the use of it
WO2001090302A3 (en) Compositions and methods for production of rna viruses and rna virus-based vector particles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2430495

Country of ref document: CA

Ref document number: 2002545626

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001998300

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001998300

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10433064

Country of ref document: US

WWR Wipo information: refused in national office

Ref document number: 2001998300

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001998300

Country of ref document: EP